针对尼古丁乙胆受体的药物发现
Dongyuan Zhang1, Hanyuan Zheng2, Kun Cui3
1Beijing Life Science Academy, Beijing, 102209, China; Neuroscience Research Institute and Department of Neurobiology, School of Basic Medical Sciences, Peking University, Key Laboratory for Neuroscience, Ministry of Education/National Health Commission, Beijing, 100191, China.
European journal of medicinal chemistry
|February 24, 2026
概括
尼古丁乙胆受体 (nAChRs) 是神经系统疾病的关键点. 研究审查了nAChR的结构,功能和药物开发,强调了治疗创新的挑战和机会.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
背景情况:
- 尼古丁乙胆受体 (nAChRs) 是关键的联结离子通道,参与神经传递和炎症.
- nAChRs与神经和精神疾病有关,包括成,阿尔茨海默氏症,精神分裂症,多动症和疼痛.
研究的目的:
- 提供nAChR结构生物学概述和不同受体亚型的重要性.
- 审查从天然毒素和小分子中发现nAChR向配体的进展.
- 讨论基于nAChR的治疗方法当前的挑战和未来的机会.
主要方法:
- 关于nAChR结构生物学近期进展的综述.
- 对nAChR亚型的生理和病理作用的分析.
- 在临床前和临床研究中对nAChR向配体进行全面的文献综述.
主要成果:
- 已经阐明了在orthosteric和allosteric位点结合联体的详细机制.
- 已经开发出许多选择性亚型的nAChR激动剂,抗剂和调节剂.
- 一些药物显示临床成功 (如戒烟),但仍然存在挑战.
结论:
- nAChRs代表了一系列疾病的重要治疗点.
- 对nAChR结构和带发育的持续研究有望改善治疗方法.
- 克服选择性,无敏化和非目标效应方面的挑战对于更广泛的临床应用至关重要.
相关概念视频
Cholinergic Receptors: Nicotinic
6.0K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
6.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.3K
Drug Discovery: Overview
12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.9K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.9K
Cholinergic Receptors: Muscarinic
5.5K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.5K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K


